ALS (motor neurone disease) trials in Spain

In Spain 15 Also abroad 226

14 of 15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Where
L'hospitalet De Llobregat, Valencia
Age
18 years and over
People
36 worldwide
Run by
Vector Y Therapeutics
See details and how to joinNCT07287397 · EU 2025-522697-37-00
Phase 1Taking people
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Where
L'hospitalet De Llobregat, Valencia
Age
18 years to 75 years
People
36 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07100119 · EU 2025-521295-60-00
Phase 3Taking people
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Where
Barcelona, Madrid, Santiago de Compostela, Valencia
Age
18 years to 80 years
People
500 worldwide
Run by
Prilenia
See details and how to joinNCT07322003
Phase 1Taking people
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Where
L'Hospitalet de Llobregat, Valencia
Age
18 years to 80 years
People
32 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07571174
Phase 1Taking people
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Where
L'hospitalet De Llobregat, Valencia
Age
18 years to 80 years
People
32 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07571200 · EU 2026-525574-19-00
Phase 2Taking people
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Where
Alicante, L'hospitalet De Llobregat, Málaga, Valencia
Age
18 years and over
People
240 worldwide
Run by
Zydus Therapeutics Inc.
See details and how to joinNCT07023835 · EU 2025-522580-15-00
Phase 2Taking people
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Where
Alicante, Barcelona, Madrid, Málaga, Seville
Age
18 years to 75 years
People
105 worldwide
Run by
PhenoNet, Inc.
See details and how to joinNCT07142291
Phase 3Taking people
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)
Where
Barcelona, L'hospitalet De Llobregat, Madrid, Santiago de Compostela, Valencia
Age
18 years and over
People
420 worldwide
Run by
Ferrer Internacional S.A.
See details and how to join2025-524002-16-00 · EU 2025-524002-16-00
No phaseTaking people
Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis
Where
Donostia / San Sebastian
Age
18 years to 85 years
People
44
Run by
University Ramon Llull
See details and how to joinNCT07413718
Phase 1/2Taking people
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)
Where
Donostia
Age
18 years to 75 years
People
90
Run by
Biogipuzkoa Health Research Institute
See details and how to joinNCT07414212 · EU 2024-519857-13-00
Phase 3Not yet taking people in Spain
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Where
Barcelona
Age
18 years to 80 years
People
412 worldwide
Run by
AB Science
See details and how to joinNCT07174492 · EU 2024-511244-12-01
Phase 3Taking people
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Where
Alicante, Barcelona, Madrid, Santiago de Compostela, Valencia
Age
18 years to 81 years
People
495 worldwide
Run by
AB Science
See details and how to joinNCT03127267
No phaseTaking people
Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study
Where
Barcelona
Age
21 years to 80 years
People
50
Run by
Parc de Salut Mar
See details and how to joinNCT06681610
Phase 2Taking people
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis (TCIM-ELAII)
Where
Alicante, Murcia
Age
18 years and over
People
100
Run by
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
See details and how to joinNCT04849065 · EU 2023-506215-17-00